🇺🇸 FDA
Patent

US 8637310

Use of a rock inhibitor to sustain primary human keratinocytes in a proliferative state

granted A61KA61K35/12A61P

Quick answer

US patent 8637310 (Use of a rock inhibitor to sustain primary human keratinocytes in a proliferative state) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K35/12, A61P, A61P17/00, A61P17/02